Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19

Author(s): Milad Shirvaliloo*

Journal Name: Current Immunology Reviews (Discontinued)

Volume 16 , Issue 1 , 2020

Graphical Abstract:


It is not unbeknownst to us that since the very onset of the COVID-19 outbreak, many patients from different age groups have suffered greatly, and in a remarkable number of cases, succumbed to their untimely demise as a result of infection with the novel coronavirus or SARS-CoV- -2. The elderly are perhaps the most vulnerable community, who stand at the pinnacle of morbidity and mortality rates due to contracting severe forms of COVID-19. Hopefully, based on the recent findings and the present evidence, there might be a number of medications that would possibly be of great prophylactic and therapeutic value to the elderly patients diagnosed with COVID-19. According to an interventional study, Thymosin α1 is arguably one such medication that has recently been indicated to be an effective therapeutic agent for inpatient management of lymphocytopenia and T cell exhaustion caused by COVID-19.

Keywords: Thymosin α1, lymphocytopenia, T cells, COVID-19, SARS-CoV-2, immunoregulatory drug.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 11 November, 2020
Page: [55 - 57]
Pages: 3
DOI: 10.2174/1573395516999201111163304
Price: $65

Article Metrics

PDF: 305